The profiling of B-cell chronic lymphocytic leukemia (B-CLL) cells at the protein level is still a major goal for advancing targeted personalized therapies. Understanding how B cells become malignant would be supported by the description of predicted responses to kinase inhibitors as nearly all cancers are guided by deregulation of protein kinase networks. In this sense, the present project looks for the profiling of the phosphopetides present in the B-CLL proteins together with the full characterization of their proteome.